Tuberc Respir Dis.  2008 Feb;64(2):87-94.

Drug Resistance Rate of New Pulmonary Tuberculosis Patients Treated from the Private Sector in 2003~2005

• Park YK
• Park YS
• Bai JY
• Kim HJ
• Lew WJ
• Chang CH
• Lee HK

Abstract

BACKGROUND: Surveillance of TB drug resistance (DR) is essential for providing information on the magnitude and trends in resistance, for developing treatment guidelines and for monitoring the effect of interventions. Up to now national surveys of drug resistance of M. tuberculosis have been conducted four times since 1994 among patients registered at health centers. The purpose of this study is to estimate the prevalence of primary drug resistance among new cases identified in private sector, and to compare it with the previous national drug resistance surveys.
METHODS
The study collected results of drug susceptibility testing (DST) performed at the Korean Institute of Tuberculosis by the request of private sector from January 2003 to December 2005, and then finally selected new cases for the analysis from the database of Korean TB Surveillance (KTBS) by matching patients' name and social identification numbers.
RESULTS
Of the 5,132 new patients included in the study, 689 (13.4%) patients were found to have drug resistance at least one drug, 530 patients (10.3%) were isoniazid resistant, 195 patients (3.8%) were multi-drug resistant (MDR), and 21 patients (0.4%) were extensively drug resistant (XDR). The rate of drug resistance tended to decrease annually but it was not statistically significant. When compared with previous national DR surveys in 2003 and in 2004 respectively, they were not significantly different.
CONCLUSION
The prevalence of DR among new cases managed in the private sector did not show significant difference from that of new patients registered in the public sector in the same year.

Keyword

New pulmonary tuberculosis patients; Drug resistance rate; Private sector

MeSH Terms

Drug Resistance
Humans
Isoniazid
Prevalence
Private Sector
Public Sector
Social Identification
Tuberculosis
Tuberculosis, Pulmonary
Isoniazid

Reference

1. Ministry of Health & Welfare, Korean National Tuberculosis Association. Report on the 7th tuberculosis prevalence survey in Korea, 1995. 1996. Seoul: Korean Institute of Tuberculosis.

2. Bai GH, Park YK, Choi YW, Bai JI, Kim HJ, Chang CL, et al. Trend of anti-tuberculosis drug resistance in Korea, 1994-2004. Int J Tuberc Lung Dis. 2007. 11:571–576.

3. Korea Center for Disease Control and Prevention, Korean Institute of Tuberculosis. Annual report on the notified tuberculosis patients in Korea (Based on Korean Tuberculosis Surveillance System), 2006. 2007. Seoul: Korean Institute of Tuberculosis.

4. Kim JH, Kim JH, Jang TW, Jung MH. Drug-resistant pulmonary tuberculosis in Kosin Medical Center. Tuber Respir Dis. 1995. 42:831–837.

5. Kim SY, Jeong SS, Kim KW, Shin KS, Park SG, Kim AK, et al. Drug-resistant pulmonary tuberculosis in a tertiary referral hospital in Korea. Korean J Intern Med. 1999. 14:27–31.

6. Lee JH, Chang JH. Drug-resistant pulmonary tuberculosis in a tertiary referral teaching hospital of Korea. Korean J Intern Med. 2001. 16:173–179.

7. Kim DK, Kim MO, Kim TH, Sohn JW, Yoon HJ, Shin DH, et al. The prevalence and risk factors of drug resistance pulmonary tuberculosis investigated at one university hospital in Seoul. Tuber Respir Dis. 2005. 58:243–247.

8. Choi JC, Lim SY, Suh GY, Chung MP, Kim HJ, Kwon OJ, et al. Drug resistance rates of Mycobacterium tuberculosis at a private referral center in Korea. J Korean Med Sci. 2007. 22:677–681.

9. WHO. Anti-tuberculosis drug resistance in the world. Report No.3: The WHO/ IUATLD global project on Anti-tuberculosis drug resistance surveillance 1999-2002. 2004. Geneva: World Health Organization.

10. WHO Geneva/ IUATLD Paris. International Union Against Tuberculosis and Lung Disease. Guidelines for surveillance of drug resistance in tuberculosis. Int J Tuberc Lung Dis. 1998. 2:72–89.

11. Korea Center for Disease Control & Prevention. Tuberculosis. 2007. Seoul: Korea Center for Disease Control & Prevention.

12. Joint Tuberculosis Committee of the British Thoracic Society. Chemotherapy and management of tuberculosis in the United Kingdom: recommendations 1998. Thorax. 1998. 53:536–548.

13. Shah NS, Wright A, Bai GH, Barrera L, Boulahbal F, Martín-Casabona N, et al. Worldwide emergence of extensively drug-resistant tuberculosis. Emerg Infect Dis. 2007. 13:380–387.